Welcome to our dedicated page for Briacell Therapeutics news (Ticker: BCTX), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics stock.
BriaCell Therapeutics Corp. develops novel immunotherapies for cancer, with a company focus on metastatic and advanced breast cancer. Its recurring news centers on Bria-IMT™, the lead cell-based immunotherapy evaluated with an immune checkpoint inhibitor in the Bria-ABC study, and on the Bria-OTS™ and Bria-OTS+™ personalized off-the-shelf immunotherapy platforms.
Company updates also cover FDA clearance activity for Bria-BRES+™, additions of clinical trial sites, presentations at oncology meetings such as ASCO, AACR and SABCS, and biomarker, survival, quality-of-life and tolerability data from breast cancer studies. BriaCell news frequently ties its clinical programs to metastatic breast cancer populations with limited prior treatment options.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2021, occurring in two parts from April 10-15 and May 17-21. The company will present data on its lead immunotherapy candidate, Bria-IMT™, focused on advanced breast cancer. Key findings include clinical and pathological analyses highlighting disease control and patient survival. Additionally, BriaCell approved the granting of 617,300 stock options to insiders, exercisable at $4.24 per share, vesting immediately, with a five-year expiration.
BriaCell Therapeutics Corp. has successfully closed its underwritten public offering, raising approximately US$25 million through the sale of 4,852,353 common units priced at US$4.25 per unit, and 1,030,000 pre-funded units at US$4.24 each. Each common unit includes one share of stock and one warrant, with a five-year exercise period. The funds will primarily support clinical trials and general working capital. Trading of the common shares and warrants began on February 24, 2021, under the symbols BCTX and BCTXW.
BriaCell Therapeutics Corp. has successfully closed its underwritten public offering, raising approximately US$25 million. The offering included 4,852,353 common units priced at US$4.25 per unit, plus 1,030,000 pre-funded units at US$4.24 per unit. The funds will be used for clinical trials, research, and general corporate activities. Additionally, the underwriter exercised its over-allotment option to purchase 882,352 warrants.
Common shares and warrants began trading on Nasdaq under symbols BCTX and BCTXW on February 24, 2021.
BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) announced a public offering of 5,882,353 units at $4.25 each, aiming to secure approximately $25 million in gross proceeds. Each unit consists of one share of common stock and one warrant, with the offering expected to close on February 26, 2021. The funds will support clinical trials and R&D, while warrants have an exercise price of $5.3125. The listing of common shares and warrants on NASDAQ is set for February 24, 2021. ThinkEquity is the sole book-running manager for this offering.
BriaCell Therapeutics Corp. has announced a public offering of 5,882,353 units, priced at US$4.25 each, to raise approximately US$25 million before expenses. Each unit comprises one share of common stock and one warrant, with warrants priced at US$5.3125 and exercisable for five years. The offering is set to close on February 26, 2021, subject to conditions. Funds will be allocated for clinical trials, research, and general corporate purposes. The securities are approved for trading on the Nasdaq under the symbols BCTX and BCTXW, starting February 24, 2021.